Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7714167 | 0.98 | KDM4E (0.57) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL24127177 | 0.92 | LMNA (0.50) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL28449360 | 0.88 | KDM4E (0.49) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL1123993 | 0.84 | KMT2A (0.61) | LMNAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL1123988 | 0.84 | KMT2A (0.61) | LMNAMAPTKDM4EALDH1A1HTT | |
| SCHEMBL6663539 | 0.82 | — | — | |
| SCHEMBL10498542 | 0.82 | LMNA (0.70) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL1123939 | 0.81 | KDM4E (0.56) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL907778 | 0.79 | POLB (0.52) | LMNAKDM4EALDH1A1POLBHTT | |
| SCHEMBL3628953 | 0.79 | ALDH1A1 (0.45) | LMNAMAPTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117000066-A | Composite reverse osmosis membrane, preparation method thereof and application thereof in generator insulating paint wastewater treatment | 四川大学 | 2023-11-07 | — | — | CN | claimed |
| EP-4178576-A1 | DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS | Emergent Product Development Gaithersburg Inc. (US) | 2023-05-17 | — | — | EP | claimed |
| WO-2022011211-A1 | DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2022-01-13 | — | — | WO | claimed |
| CN-105452233-B | Piperidine and azepane derivatives as prokineticin receptor modulators | 武田药品工业株式会社 | 2017-12-08 | — | — | CN | claimed |
| CN-102952086-B | Preparation method of 2-morpholinyl-substituted pyrimidine compounds | TIANJIN SCIPHARMACN LTD | 2013-08-28 | — | — | CN | claimed |
| CN-101553233-A | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-101516379-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-08-26 | — | — | CN | claimed |
| WO-2009066084-A1 | 2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-28 | — | — | WO | claimed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| CN-1960726-A | Composition comprising a jnk inhibitor and cyclosporin | APPLIED RESEARCH SYSTEMS (AN) | 2007-05-09 | — | — | CN | claimed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250352539-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2025-11-20 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20030114446-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2003-06-19 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| CN-1106007-A | Novel sulfonylamino pyrimidines | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
| US-4565864-A | INTERMEDIATES FOR BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | LMNA 2842/4885MAPT 3186/4885KDM4E 1533/4885 |
| US-20250352539-A1 | COMBINATION THERAPY FOR TREATING CANCER | PARP1, ATR, PARP11 | LMNA 2436/4885MAPT 1726/4885KDM4E 2398/4885 |
| US-20250179079-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | CGAS, XDH, NPY1R | LMNA 1664/4885MAPT 4359/4885KDM4E 1682/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | LMNA 2827/4885MAPT 3191/4885KDM4E 1516/4885 |
| US-20030114446-A1 | Pyrimidine compounds | CCNO, CNR1, CBR1 | LMNA 2838/4885MAPT 4160/4885KDM4E 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.